Determination of serum anti-Mullerian hormone levels in a low-prognosis women treated in-vitro fertilization/intracytoplasmic sperm injection: A cohort study
Background: Outcome prediction of participants treated with in-vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI) using anti-Mullerian hormone (AMH) concentration has been widely used. According to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) definition, low prognosis Bologna responders have changed from poor. This definition divides low prognosis into 4 groups.
Objective: The purpose of this study was to assess blood AMH levels in the group of women treated with IVF/ICSI who were thought to have a low prognosis.
Materials and Methods: A retrospective cohort study among 252 suspected lowprognosis group participants was assessed between January 2016 and December 2019 at Morula IVF, National hospital, Surabaya, Indonesia. Observed AMH serum levels and pregnancy rates were compared among 4 subgroups.
Results: The AMH cutoff value was 1.7 ng/mL with a sensitivity of 86.7% and a specificity of 70% for diagnosing low-prognosis women using POSEIDON criteria. There was no difference in the pregnancy rate between those groups (p-value > 0.05).
Conclusion: AMH levels may indicate a poor prognosis for women having IVF/ICSI in accordance with POSEIDON guidelines. To predict the poor prognosis in women, the cutoff value must be identified.
Key words: Prognosis, Assisted reproductive technics, Gonadal hormone, Fertilization in vitro, Reproductive health.
 Kresna A, Lestari TD, Kasman AM, Luqman EM. Calcium ionophore as oocyte activator to fertilization rate and cleavage level on kacang goat post intracytoplasmic sperm injection (ICSI). Teikyo Med J 2021; 44: 1031-1037.
 Rahayu FK, Dwiningsih SR, Sa’adi A, Herawati L. Effects of different intensities of exercise on folliculogenesis in mice: Which is better? Clin Exp Reprod Med 2021; 48: 43-49.
 Mohammadzadeh M, Fesahat F, Khoradmehr A, Khalili MA. Influential effect of age on oocyte morphometry, fertilization rate and embryo development following IVF in mice. Middle East Fertil Soc J 2018; 23: 117-120.
 Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, van Golde RJT, Hoek A, et al. Cumulative live birth rates in low-prognosis women. Hum Reprod 2019; 34: 1030-1041.
 Lukaszuk K, Liss J, Kunicki M, Jakiel G, Wasniewski T, Woclawek-Potocka I, et al. Anti-Mullerian hormone (AMH) is a strong predictor of live birth in women undergoing assisted reproductive technology. Reprod Biol 2014; 14: 176-181.
 Alanazi H, Bushaqer N, Ayyoub H, Dayoub N, Hassan S. Antimullerian hormone (AMH) level and IVF/ICSI cycle outcome in expected poor responders. Middle East Fertil Soc J 2018; 23: 246-250.
 Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: Is there a need for revision? Hum Reprod 2014; 29: 1842-1845.
 Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria-the why. Front Endocrinol 2018; 9: 461.
 The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: Ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020; 2020: 1-13.
 Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach. Hum Reprod Update 2013; 19: 26-36.
 Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014; 20: 370-385.
 La Marca A, Ferraretti AP, Palermo R, Ubaldi FM. The use of ovarian reserve markers in IVF clinical practice: A national consensus. Gynecol Endocrinol 2016; 32: 1-5.
 Clemente Nd, Racine C, Pierre A, Taieb J. Anti-Mullerian hormone in female reproduction. Endocrine Rev 2021; 42: 753-782.
 Racoubian E, Aimagambetova G, Finan RR, Almawi WY. Age-dependent changes in anti-Mullerian hormone levels in Lebanese females: Correlation with basal FSH and LH levels and LH/FSH ratio: A cross-sectional study. BMC Women’s Health 2020; 20: 134.
 Li R, Gong F, Zhu Y, Fang W, Yang J, Liu J, et al. Anti-Mullerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: A prospective, multi-centre, observational study. Reprod Biomed Online 2016; 33: 506-512.
 Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S, et al. Clinical application of serum anti-Mullerian hormone as an ovarian reserve marker: A review of recent studies. J Obstet Gynaecol Res 2018; 44: 998-1006.
 Zebitay AG, Cetin O, Verit FF, Keskin S, Sakar MN, Karahuseyinoglu S, et al. The role of ovarian reserve markers in prediction of clinical pregnancy. J Obstet Gynaecol 2017; 37: 492-497.
 Stracquadanio M, Ciotta L, Palumbo MA. Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women. Gynecol Endocrinol 2018; 34: 223-228.
 Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet 2014; 31: 1311-1316.
 Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in anti-Mullerian hormone and ovarian reserve. Int J Endocrinol 2013; 2013: 818912.
 Elchuri SV, Patterson BC, Brown MR, Buchanan I, Mertens AC, Meacham LR. Anti-Mullerian hormone levels in American girls by age and race/ethnicity. J Pediatr Endocrinol Metab 2015; 28: 189-193.
 Bedenk J, Vrtacnik-Bokal E, Virant-Klun I. The role of anti-Mullerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89-100.
 Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod 2012; 27: 594-608.
 Gleicher N, Weghofer A, Kim A, Barad DH. The impact in older women of ovarian FMR1 genotypes and subgenotypes on ovarian reserve. PLoS One 2012; 7: e33638.
 Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic markers of ovarian follicle number and menopause in women of multiple ethnicities. Hum Genet 2012; 131: 1709-1724.
 Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti- Müllerian hormone (AMH) analogues in reproductive medicine. J Assist Reprod Genet 2017; 34: 1105-1113.
 Kedem A, Haas J, Geva LL, Yerushalmi G, Gilboa Y, Kanety H, et al. Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles. PLoS One 2013; 8: e81629.
 Chinta P, Antonisamy B, Mangalaraj AM, Kunjummen AT, Kamath MS. POSEIDON classification and the proposed treatment options for groups 1 and 2: Time to revisit? A retrospective analysis of 1425 ART cycles. Hum Reprod Open 2021; 2021: hoaa070.
 Adanas Aydin G, Yavuz A, Terzi H, Kutlu T. Assessment of the relationship of basal serum anti-Mullerian hormone levels with oocyte quality and pregnancy outcomes in patients undergoing ICSI. Iran J Reprod Med 2015; 13: 231-236.